fpr

FPR A14 is an agonist of formyl peptide receptor (FPR) and induces cell differentiation.

FPR Agonist 43 is a dual agonist of formyl peptide receptor 1 and formyl peptide receptor 2 (FPR2) ALX.

Cefprozil monohydrate (Cefprozil) is a second-generation cephalosporin-type antibiotic.

FPR2 agonist 2 is a potent FPR2 agonist with blood-brain barrier permeability that acts on h-FPR2 (EC50: 0.13 nM), inhibiting the production of pro-inflammatory cytokines, counteracting changes in mitochondrial function, and inhibiting caspase-3 activity.

Cofpropamine, a caffeine derivative that inhibits polyadenylation, enhances the suppressive effects of Cyclophosphamide in animal models of rat adjuvant arthritis and mouse collagen-induced arthritis.

Compound CMC23, an FPR2 agonist, mitigates lactate dehydrogenase release in LPS-stimulated cultures and reduces pro-inflammatory IL-1β and IL-6 levels. It also attenuates phosphor-STAT3 levels through the STAT3 SOCS3 signaling pathway [1].

Compound 25b, an FPR1 antagonist, exhibits potent inhibition of the formyl peptide receptor 1 with an IC50 of 70 nM. It concurrently hampers cell proliferation and triggers apoptosis, diminishing cell growth and migration, yet paradoxically augments angiogenesis [1].

Compound 20, also known as FPR2 agonist 4, selectively activates FPR2 with an EC50 of 0.2 nM.

Compound 24a, an FPR1 antagonist, demonstrates potent inhibition of the formyl peptide receptor 1 (FPR1) with an IC50 value of 25 nM. It impedes cell proliferation and promotes apoptosis, thereby inhibiting cell growth. This compound also attenuates cell migration and concurrently promotes angiogenesis [1].

Efprezimod alfa, an active peptide, can be utilized for various biochemical studies.

Cefprozil (Cefzil) is a novel cephalosporin antibiotic with antiviral activity for the study of immune system disorders.

N-Formyl-Met-Leu-Phe (N-Formyl-MLF) (fMLF) is a synthetic peptide that acts as an agonist at formyl peptide receptors (FPR; Ki = 0.8 pM).

MMK 1 acetate is an agonist of formyl peptide receptor 2 (FPR2), which was previously known as formyl peptide receptor-like 1 (FPRL1) [1].

Ac9-25 acetate is an annexin AI peptide and activates the neutrophil reduced nicotinamide adenine dinucleotide phosphate oxidase through FPR but not through FPRL1.

Ac9-25 TFA, an N-terminal peptide of Annexin I, functions as a formyl peptide receptor (FPR) agonist, activating neutrophil NADPH oxidase via FPR [1] [2].

PD176252 is a potent BB1 and BB2 antagonist with inhibitory effects on BB1 and BB2 receptors.PD176252 acts as a small molecule GRPR inhibitor and FPR1 FPR2 agonist to inhibit the growth and proliferation of a variety of cancer cells.

Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6 1.9 6.2 nM).

N-Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a formyl peptide receptor 1 (FPR1) antagonist that increases pain effects and inhibits the antinociceptive activity of annexin. Boc-FLFLF is extensively used in FPR research.

N-Formyl-MMYALF TFA is a mitochondrial N-formyl peptide known for its ability to deplete calcium ions in the endoplasmic reticulum. Additionally, it inhibits the FPR-1-mediated chemotactic response of PMNs to bacterial peptides.

Ebopiprant (OBE022) is an orally available, selective and potent prostaglandin F2α (PGF2α) receptor antagonist that interferes with the binding of PGF0126α to the FPR and can be used in the study of obesity.

{Boc}-Phe-Leu-Phe-Leu-Phe TFA is a selective antagonist of the formyl peptide receptor (FPR) family, effectively inhibiting FPR-mediated actions [1].

Prostaglandin J2 (PGJ2), a derivative of Prostaglandin D2 (PGD2), serves as a potent agonist for PGD2 receptors (DP), exhibiting affinity constants (K i) of 0.9 nM and 6.6 nM for hDP and hCRTH2 receptors, respectively. It activates cyclic AMP production with an EC50 of 1.2 nM, induces oxidative stress, neuronal apoptosis, and promotes the accumulation of ubiquitinated (Ub) proteins. Notably, PGJ2's neurotoxic properties are implicated in the progression of neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD) [1] [2] [3] [4].

PDC31 (THG113.31; ILGHXDYK) is a D-amino acid-based oligopeptide that acts as an allosteric and non-competitive inhibitor of the FP Prostaglandin Receptor, used primarily as a smooth muscle contractile agent. It effectively reduces the strength and duration of uterine contractions in vivo, offering potential for preterm labor and primary dysmenorrhea (PD) research. Additionally, PDC31 enhances the Ca2+-dependent large-conductance K+-channel in human myometrial cells [1] [2].

{Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a selective antagonist of the formyl peptide receptor (FPR) family, effectively inhibiting receptor activity in response to formyl peptides.